Angiogenic Imaging in Pulmonary Arterial Hypertension

• Register: ClinicalTrials.gov
• Last refreshed on: 10 May 2021
• Main ID: NCT03166306
• Date of registration: 09/05/2017
• Prospective Registration: Yes
• Primary sponsor: Brigham and Women's Hospital
• Public title: Angiogenic Imaging in Pulmonary Arterial Hypertension AIPAH
• Scientific title: Angiogenic Imaging in Pulmonary Arterial Hypertension
• Date of first enrolment: May 1, 2018
• Target sample size: 5
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03166306
• Study type: Interventional
• Study design: Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
• Phase: Phase 1/Phase 2

Countries of recruitment

United States

Contacts

• Name: Paul B Yu, MD PhD
• Affiliation: Brigham and Women's Hospital

• Name: Marcelo F Di Carli, MD
• Affiliation: Brigham and Women's Hospital

• Name: Ivana Nikolic, MD
• Affiliation: Brigham and Women's Hospital

• Name: Aaron B Waxman, MD PhD
• Affiliation: Brigham and Women's Hospital

Key inclusion & exclusion criteria

Inclusion Criteria:

- Age =18 years at screening;

- Documented diagnosis Group 1 PAH confirmed by resting mean pulmonary artery pressure
greater than 25 mm of Hg, pulmonary vascular resistance greater than 3 Wood units, and
pulmonary wedge pressure less than 12 mm of Hg measured by right heart catheterization
at the time of diagnosis and before initiation of PAH specific therapy clinically
stable for 60 or more days prior to enrollment, defined as no changes in medical
regimen and no hospitalizations;

- Prior diagnosis of exercise-associated PAH (EPAH) confirmed by normal resting
hemodynamics (mean pulmonary artery pressure < 25 mm of Hg, pulmonary artery wedge
pressure < 12 mm of Hg, and pulmonary vascular resistance < 3 Wood units) measured by
right heart catheterization at rest and abnormal hemodynamic response to exercise
characterized by increase in mean pulmonary artery pressure > 30 mm Hg, pulmonary
artery wedge pressure < 20 mm Hg, and pulmonary vascular resistance > 1 Wood unit at
peak exercise and cardiac output less than 10 L/min before initiation of any PAH
specific therapy. Patients need to be clinically stable for 60 or more days prior to
enrollment, defined as no changes in medical regimen and no hospitalizations;

- Willingness to participate as evidenced by signing of the informed consent;

Exclusion Criteria:

- Prior history of chronic infectious disease, tuberculosis, or severe fungal disease;
chronic hepatitis B or C infection; renal insufficiency; interstitial pneumonitis,
bronchiectasis, or pulmonary fibrosis; known chronic pericardial effusion, pleural
effusion, or ascites; chronic liver disease; myeloproliferative disorders in the past
5 years; non-basal cell malignancy or treated lymphoproliferative disease within the
past 5 years; known HIV positive; life expectancy of <3 years;

- Chronic inflammatory condition such as lupus or rheumatoid arthritis, ulcerative
colitis or Crohn's disease;

- White blood cell count <2,500/uL, hematocrit < 30 percent, or platelet count <
50,000/uL;

- Elevated liver transaminase levels (AST or ALT) 20 % above upper limit of normal (ULN)
or albumin 20 % below the lower limit of normal (LLN);

- Creatinine clearance < 45 mL/min as estimated with the Cockroft-Gault equation;

- Women who are pregnant or breastfeeding;

- Men or women who plan to have children during the study period or who are unwilling to
use effective forms of contraception;

- Known active cancer;

- Chronic use of oral steroid therapy or other immunosuppressive or biologic response
modifiers (see Exclusionary Medication List in Manual of Operations). Eligible study
participants will be encouraged to have up to date pneumococcal and influenza
vaccinations as recommended based on their age and underlying medical conditions;

- Evidence of interstitial pneumonitis, bronchiectasis, or pulmonary fibrosis in the
past 12 months by chest X-ray. For participants who have not had a chest X-ray during
the 12 months prior to enrollment in the study, a chest X-ray will be obtained at
baseline as part of the study protocol;

- New York Heart Association Class IV congestive heart failure;

- Severe asthma or COPD defined by FEV1 less than 50% predicted and FEV1/FVC less than
70% per PFTs in the past 12 months;

- Active tobacco use during the prior 10 years;



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Pulmonary Arterial Hypertension

Exercise Associated Pulmonary Arterial Hypertension

Intervention(s)

Diagnostic Test: PET-CT Imaging with [89Zr]-bevacizumab

Primary Outcome(s)

Distal pulmonary SUV of [89Zr]-bevacizumab [Time Frame: Baseline measurement at entry into study]

Secondary Outcome(s)

Change in distal pulmonary SUV of [89Zr]-bevacizumab [Time Frame: Measurement at 12 months following initial measurement]

Secondary ID(s)

2017P000249

Source(s) of Monetary Support

Please refer to primary and secondary sponsors